1. Home
  2. VALU vs CGEN Comparison

VALU vs CGEN Comparison

Compare VALU & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Value Line Inc.

VALU

Value Line Inc.

N/A

Current Price

$32.95

Market Cap

311.5M

Sector

Finance

ML Signal

N/A

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.15

Market Cap

270.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VALU
CGEN
Founded
1931
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
311.5M
270.4M
IPO Year
1995
2001

Fundamental Metrics

Financial Performance
Metric
VALU
CGEN
Price
$32.95
$2.15
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
1.2K
545.2K
Earning Date
03-16-2026
05-18-2026
Dividend Yield
3.72%
N/A
EPS Growth
8.91
N/A
EPS
1.92
N/A
Revenue
$36,257,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$75.09
P/E Ratio
$17.01
N/A
Revenue Growth
1.08
N/A
52 Week Low
$32.16
$1.30
52 Week High
$40.50
$3.24

Technical Indicators

Market Signals
Indicator
VALU
CGEN
Relative Strength Index (RSI) 35.47 33.33
Support Level N/A $1.46
Resistance Level $38.30 $2.35
Average True Range (ATR) 0.77 0.19
MACD -0.04 -0.08
Stochastic Oscillator 8.16 1.61

Price Performance

Historical Comparison
VALU
CGEN

About VALU Value Line Inc.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: